CCCC (C4 Therapeutics) Inventories, Inventories Adjustments: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCCC C4 Therapeutics Inc CCCC
48 GF Score
Price $3.55
GF Value $2.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is C4 Therapeutics Inventories, Inventories Adjustments?

C4 Therapeutics CCCC -5.46% 48 Inventories, Inventories Adjustments is $0.00 Mil as of Jun. 2026. GuruFocus rates CCCC with a GF Score™ of 48/100 and a GF Value™ of $2.03 (Significantly Overvalued). The stock has 4 warning signs investors should review.

C4 Therapeutics's Inventories, Inventories Adjustments for the quarter that ended in Jun. 2026 was $0.00 Mil.

C4 Therapeutics Inventories, Inventories Adjustments Historical Data

* Premium members only.

The historical data trend for C4 Therapeutics's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C4 Therapeutics Inventories, Inventories Adjustments Chart

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Inventories Adjustments
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

C4 Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CCCC
48GF Score
C4 Therapeutics Inc CCCC
Inventories, Inventories Adjustments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C4 Therapeutics Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

What does a Inventories, Inventories Adjustments of $0.00 Mil mean?
C4 Therapeutics (CCCC) has a Inventories, Inventories Adjustments of $0.00 Mil as of Jun. 2026. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on C4 Therapeutics and its competitors.
Is C4 Therapeutics' Inventories, Inventories Adjustments too high?
C4 Therapeutics' current Inventories, Inventories Adjustments is $0.00 Mil. Overall, C4 Therapeutics has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C4 Therapeutics' Inventories, Inventories Adjustments compare to DNA and PBYI?
C4 Therapeutics' Inventories, Inventories Adjustments of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Inventories Adjustments for a Biotechnology company?
A good Inventories, Inventories Adjustments depends on the Biotechnology industry context. However, Inventories, Inventories Adjustments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Inventories Adjustments mean?
A high Inventories, Inventories Adjustments can signal that a stock is expensive relative to its fundamentals. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on C4 Therapeutics and its competitors. C4 Therapeutics's current Inventories, Inventories Adjustments is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C4 Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, C4 Therapeutics (CCCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.03, compared to a current price of $3.55 — trading 74.9% above its estimated fair value. The current Inventories, Inventories Adjustments is $0.00 Mil. C4 Therapeutics' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Inventories Adjustments calculated?
Inventories, Inventories Adjustments is calculated from a company's financial statements. For C4 Therapeutics (CCCC), the current Inventories, Inventories Adjustments is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C4 Therapeutics (CCCC) Overvalued in 2026?

Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued. The current stock price of $3.55 is trading 74.9% above its estimated GF Value™ of $2.03. GuruFocus considers C4 Therapeutics to be Significantly Overvalued.

Key valuation signals for CCCC:

  • Inventories, Inventories Adjustments: $0.00 Mil
  • GF Value™: $2.03 vs. price of $3.55 (74.9% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C4 Therapeutics Business Description

Address 490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
48GF Score

Get the complete analysis for CCCC

Inventories, Inventories Adjustments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price
$2.03
GF Value